Edition:
United States

Xenon Pharmaceuticals Inc (XENE.OQ)

XENE.OQ on NASDAQ Stock Exchange Global Market

7.85USD
21 Jun 2018
Change (% chg)

-- (--)
Prev Close
$7.85
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
20,353
52-wk High
$9.10
52-wk Low
$2.15

Select another date:

Tue, May 15 2018

BRIEF-Xenon Presents Positive Xen1101 Tms Pharmacodynamic Phase 1 Data At 14Th Eilat Conference

* XENON PRESENTS POSITIVE XEN1101 TMS PHARMACODYNAMIC PHASE 1 DATA AT 14TH EILAT CONFERENCE

BRIEF-Xenon Pharmaceuticals Q1 Net Loss Per Common Share $0.21

* XENON PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Xenon Pharmaceuticals Enters Into At-The-Market Equity Offering Sales Agreement With Stifel, Nicolaus & Co

* XENON PHARMACEUTICALS INC - ON MAY 8, CO ENTERED INTO AN AT--MARKET EQUITY OFFERING SALES AGREEMENT WITH STIFEL, NICOLAUS & COMPANY - SEC FILING

BRIEF-Xenon Pharmaceuticals To Host Conference Call To Discuss Q1 2018 Financial Results

* XENON PHARMACEUTICALS TO HOST CONFERENCE CALL AND WEBCAST TO DISCUSS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE Source text for Eikon: Further company coverage:

BRIEF-Xenon Pharma, Teva Pharma Terminate Development & License Agreement

* XENON PHARMACEUTICALS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Xenon Advances Second Proprietary Epilepsy Product Into Clinic With Initiation Of Xen901 Phase 1 Clinical Trial

* XENON PHARMACEUTICALS ADVANCES SECOND PROPRIETARY EPILEPSY PRODUCT INTO THE CLINIC WITH INITIATION OF XEN901 PHASE 1 CLINICAL TRIAL Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Xenon Pharmaceuticals Expects To Have Ongoing XEN1101 Phase 1 Clinical Trial Completed By Mid-Year

* XENON PHARMACEUTICALS INC - EXPECT TO HAVE ONGOING XEN1101 PHASE 1 CLINICAL TRIAL COMPLETED BY MID-YEAR

Select another date: